3 Promising Penny Stocks With Market Caps Over $100M

As the U.S. stock market continues to inch higher, buoyed by encouraging inflation data and positive developments in China-U.S. trade talks, investors are exploring diverse opportunities for growth. Penny stocks, despite their vintage name, remain a relevant investment area offering potential value through smaller or newer companies with strong financial foundations. In this article, we explore several penny stocks that stand out as hidden gems with the potential to deliver impressive returns while maintaining stability amidst current market conditions.

Advertisement

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapRewards & Risks
SideChannel (SDCH)$0.04755$11.56M✅ 4 ⚠️ 2 View Analysis >
Imperial Petroleum (IMPP)$3.02$106.34M✅ 4 ⚠️ 1 View Analysis >
New Horizon Aircraft (HOVR)$1.12$34.21M✅ 4 ⚠️ 5 View Analysis >
Waterdrop (WDH)$1.43$531.64M✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)$1.13$186.68M✅ 4 ⚠️ 1 View Analysis >
Perfect (PERF)$1.81$182.31M✅ 4 ⚠️ 0 View Analysis >
Table Trac (TBTC)$4.72$21.94M✅ 2 ⚠️ 2 View Analysis >
Flexible Solutions International (FSI)$4.31$54.7M✅ 1 ⚠️ 2 View Analysis >
BAB (BABB)$0.8265$6.17M✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)$4.12$84.5M✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 708 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Anixa Biosciences (ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of $109.52 million.

Operations: Anixa Biosciences, Inc. does not report any revenue segments.

Market Cap: $109.52M

Anixa Biosciences, Inc., with a market cap of US$109.52 million, is a pre-revenue biotechnology firm focusing on oncology therapies and vaccines. The company recently completed enrollment for its Phase 1 breast cancer vaccine trial, funded by the U.S. Department of Defense, showing promising immune response results that may lead to Phase 2 trials. Despite being unprofitable and having increased losses over the past five years, Anixa remains debt-free with sufficient cash runway for over a year. Its management and board are experienced, supporting ongoing innovative efforts in immuno-oncology despite existing financial challenges.

ANIX Debt to Equity History and Analysis as at Jun 2025
ANIX Debt to Equity History and Analysis as at Jun 2025

Outdoor Holding (POWW)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Outdoor Holding Company designs, produces, and markets ammunition and components for various customers including sport shooters, hunters, and law enforcement agencies, with a market cap of $161.49 million.

Operations: The company generates revenue from two main segments: Ammunition, contributing $81.62 million, and Marketplace, accounting for $50.36 million.

Market Cap: $161.49M

Outdoor Holding Company, with a market cap of US$161.49 million, is facing financial challenges as it remains unprofitable and has seen increased losses over the past five years. Despite this, the company benefits from experienced board leadership and a strong cash position that exceeds its total debt. Recent executive changes include Steven F. Urvan's appointment as CEO following Jared Smith's resignation, which was not due to any operational disagreements. The company has received a Nasdaq compliance notice due to governance issues but plans to address these concerns promptly while maintaining its current stock listing status.

POWW Financial Position Analysis as at Jun 2025
POWW Financial Position Analysis as at Jun 2025

CS Disco (LAW)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CS Disco, Inc. offers cloud-native and AI-powered legal products for various legal processes, with a market cap of $263.29 million.

Operations: The company generates revenue from its Software & Programming segment, totaling $145.92 million.

Market Cap: $263.29M

CS Disco, Inc., with a market cap of US$263.29 million, is navigating financial hurdles as it remains unprofitable, with losses increasing at 17.6% annually over the past five years. Despite trading at 78% below its estimated fair value and experiencing significant insider selling recently, the company maintains a strong cash runway exceeding three years without debt obligations. The management team is relatively new but supported by an experienced board averaging 4.2 years in tenure. Recent guidance projects fiscal year revenue between US$146 million to US$158 million, reflecting modest growth expectations amid ongoing challenges in achieving profitability.

LAW Revenue & Expenses Breakdown as at Jun 2025
LAW Revenue & Expenses Breakdown as at Jun 2025

Seize The Opportunity

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:ANIX

Anixa Biosciences

A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

Flawless balance sheet with very low risk.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0768.0% undervalued
278 users have followed this narrative
1 users have commented on this narrative
38 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.5% undervalued
76 users have followed this narrative
0 users have commented on this narrative
18 users have liked this narrative
TO
Tokyo
ABI logo
Tokyo on Anheuser-Busch InBev ·

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

Fair Value:€89.4521.3% undervalued
4 users have followed this narrative
3 users have commented on this narrative
2 users have liked this narrative
OS
oscargarcia
AMZN logo
oscargarcia on Amazon.com ·

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.

Fair Value:US$2802.3% undervalued
59 users have followed this narrative
1 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

CH
BAJAJ-AUTO logo
Chimichanga696 on Bajaj Auto ·

Bajaj Auto has seen a correction in its stock price after a strong rally, making it an attractive opportunity for investors.

Fair Value:₹15k31.2% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
RockeTeller
BGD logo
RockeTeller on Barton Gold Holdings ·

Aussie’s Barton Gold, No Debt Miner with 1 Mill That Changes Everything

Fair Value:AU$22.4495.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MR
MRT23
ASIC logo
MRT23 on Ategrity Specialty Insurance Company Holdings ·

ASIC is a technology-differentiated E&S insurer compounding book value with a structurally improving combined ratio

Fair Value:US$3035.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.235.6% undervalued
69 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9326.8% undervalued
1396 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74018.2% undervalued
31 users have followed this narrative
3 users have commented on this narrative
32 users have liked this narrative